Fig. 1From: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in GermanyPatient disposition. Numbers of patients in the compassionate use program on which the baseline data analysis and safety analysis were based. *22 patients had not yet passed the 120-day wash-out period for previous nusinersen treatment before the CUP was terminatedBack to article page